Abstract
Edwards, F. R. and Whitwell, F. (1974).Thorax, 29, 654-658. Use of BCG as an immunostimulant in the surgical treatment of carcinoma of the lung. Cell-mediated immunity to cancer cells would appear to exert some control over the extension of tumour growth, and stimulation of this factor might result in increased survival after surgical treatment of the tumour. Of the various agents used as stimulators in experimental work, BCG would seem to be the most convenient to use in man. A single dose of BCG-Glaxo (500,000 organisms) was given subdermally 10 days after excision of lung carcinoma. The length of survival was used as the index of the effect of the BCG.
Two trials were initiated, the first to study the safety of BCG and a survival study of 120 consecutive cases (60 used as controls). This is an interim report at two years of this trial. The main features at this stage show that the overall survival rate has increased from 38% in the controls to 52% in the BCG group. In the squamous-cell group survival has risen from 50% to 62% and, in those with positive nodes, from 33% to 53%. In the oat-cell group, two-year survival has risen from 11% in the controls to 50% in the BCG groups, though the numbers are small. Although encouraging, the results are not statistically significant.
The second trial is a randomized trial in which five surgeons have taken part, and 500 consecutive cases of lung resection for carcinoma are documented (250 control and 250 BCG). It is too early for results to be assessed in this group.
It is hoped that at three, four, and five years more favourable survival figures will be obtained.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BLACK M. M., SPEER F. D. Sinus histiocytosis of lymph nodes in cancer. Surg Gynecol Obstet. 1958 Feb;106(2):163–175. [PubMed] [Google Scholar]
- GORDON-TAYLOR G. The incomputable factor in cancer prognosis. Br Med J. 1959 Feb 21;1(5120):455–462. doi: 10.1136/bmj.1.5120.455. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Halpern B. N., Biozzi G., Stiffel C., Mouton D. Inhibition of tumour growth by administration of killed corynebacterium parvum. Nature. 1966 Nov 19;212(5064):853–854. doi: 10.1038/212853a0. [DOI] [PubMed] [Google Scholar]
- OLD L. J., BENACERRAF B., CLARKE D. A., CARSWELL E. A., STOCKERT E. The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res. 1961 Oct;21:1281–1300. [PubMed] [Google Scholar]
- OLD L. J., CLARKE D. A., BENACERRAF B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959 Jul 25;184(Suppl 5):291–292. doi: 10.1038/184291a0. [DOI] [PubMed] [Google Scholar]
- SENSENIG D. M., ROSSI N. P., EHRENHAFT J. L. Results of the surgical treatment of bronchogenic carcinoma. Surg Gynecol Obstet. 1963 Mar;116:279–284. [PubMed] [Google Scholar]
- Sjögren H. O., Ankerst J. Effect of BCG and allogeneic tumor cells on adenovirus type 12 tumorigenesis in mice. Nature. 1969 Mar 1;221(5183):863–864. doi: 10.1038/221863a0. [DOI] [PubMed] [Google Scholar]
- Southam C. M. Evidence of immunological reactions to autochthonous cancer in man. Eur J Cancer. 1965 Nov;1(3):173–181. doi: 10.1016/0014-2964(65)90045-9. [DOI] [PubMed] [Google Scholar]
- Takita H. Effect of postoperative empyema on survival of patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1970 May;59(5):642–644. [PubMed] [Google Scholar]
- WHITWELL F. The histopathology of lung cancer in Liverpool: a survey of bronchial biopsy histology. Br J Cancer. 1961 Sep;15:429–439. doi: 10.1038/bjc.1961.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wyburn-Mason R. Immunity to cancer. Br Med J. 1969 Jun 21;2(5659):765–766. doi: 10.1136/bmj.2.5659.765-c. [DOI] [PMC free article] [PubMed] [Google Scholar]